Moreover, a study of pembrolizumab plus margetuximab for second-line and beyond treatment in patients with advanced HER2-positive G/GEJ adenocarcinoma confirmed the synergistic antitumor effects of HER2-targeted agents and ICIs [56]. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.